Compared to conventional PI3K inhibitors, the PROTAC molecule exhibits stronger anti-tumor effects and significant anti-proliferative activity in two lapatinib-resistant breast cancer cell lines, MDA-MB-453 and JIMT179,82. Here, PIK3CA is linked to neoplasm.